Express Press Release Distribution

Accounting
Advertising
Aerospace
Agriculture
Apparel & Fashion
Automotive
Biotech
Chemicals
Computers
Construction
Consumer Services
Defense
Education
Electronics
Energy
Entertainment
Environment
Financial
Food & Beverage
Government
Healthcare
Human Resources
Industrial
International Trade
Internet & Online
Law
Management
Marketing
Media
Non Profit
Pharmaceuticals
Real Estate
Retail
Semiconductors
Small Business
Software
Sports
Telecommunications
Transportation / Logistics
Travel

EPR Archived News

Archived News 2012
~ April
~ March
~ February
~ January

Archived News 2011
~ December
~ November
~ October
~ September
~ August
~ July
~ June
~ May
~ April
~ March
~ February
~ January

Archived News 2010
Archived News 2009
Archived News 2008
Archived News 2007
Archived News 2006
Archived News 2005
Archived News 2004

 

New Arthritis Treatment Promises Good Results

Released on = April 11, 2006, 2:41 pm

Press Release Author = Jeff Conrad

Industry = Healthcare

Press Release Summary = There is a new treatment option which gives hope to all,
suffering from arthritis.
The three biologicals so called antagonists TNF-alpha Etanercept, Adalimumab,
Infliximab have already been present in the market for several years, and there
exist results of long-run investigation of the preparations.

Press Release Body = Many people are used to thinking of arthritis as of the disease
prevailing in people over 60. It is incorrect. Elderly people are thought to be
mostly affected by the disease because if they have not got proper treatment in
time, arthritis manifestation is really dreadful.

Actually, depending on the type of arthritis, 35-45-year-old people are more often
affected by the disease. There exists also juvenile arthritis, which manifests
itself in young age.
Now you have a notion of how important it is to diagnose arthritis in its early stages.

It’s important to timely consult specialist of rheumatological centres. The
specialists are experienced in the modern methods of arthritis treatment.

There is a new treatment option which gives hope to all, suffering from arthritis.
The three biologicals so called antagonists TNF-alpha Etanercept, Adalimumab,
Infliximab have already been present in the market for several years, and there
exist results of long-run investigation of the preparations.

The most extensive study of rheumatoid arthritis, so called Re-Act study, was
carried out with the assistance of 6000 patients of 4000 centers in 11 European
countries. The results have been published only at the end of 2004.

Patients received a hypodermic injection of 40 mg of Adalimumab once in 2 weeks. In
12 weeks the results of treatment were explored and evaluated.
The results were as follows:
The results were amazing!
Pain in joint when pressed reduced from 13% till 3%, e.g. in 77% of cases!!! 23% of
patients did not suffer pain in joint when pressed.

Swelling in joints reduced from 10% till 3%, e.g. in 70% of cases!!!! 25% of
patients marked disappearance of swelling in joints after12 weeks of the treatment.
As early as after the first injection, 70% of the patients suffering pain in joints
when pressed and 57% of the patients with join swelling pointed to the good results
of the treatment.

One fourth of the patients marked the elimination of pain after 12 weeks of the
treatment.
Some further results of the Re-Act study showed further health improvement.

But the medicines are very costly. In Europe prescription of the medicines is under
control and is in connection with the certain illness severity score.
It is worth underlining once again that the preparations might have side actions and
have to be prescribed by an experienced doctor.

Therapeutic effect of the basis medicines becomes apparent in 1-2 months, this of
biologics – in several days (or weeks).

Read more about Arthritis and how to treat Arthritis at
www.health-info-site.net/Arthritis.html

Web Site =
Contact Details = Jeff Conrad||Collins Avenue||MIAMI ,
22358||$$country||||00392005678||agencysuccess@yahoo.de||

  • Printer Friendly Format
  • Back to previous page...
  • Back to home page...
  • Submit your press releases...
  •